Beijing Wantai Biological Pharmacy Enterprise (SHA:603392), a Chinese vaccine developer and manufacturer of medical products, plans to start a large trial of its nasal spray-based COVID-19 vaccine candidate next month, Reuters news agency reported on Thursday.
According to an entry posted on the Chinese Clinical Trial Registry on Wednesday, the company aims to recruit 40,000 adults for the Phase III clinical trial. Participants would be given two doses of the Beijing Wantai vaccine candidate or a placebo vaccine at a two-week interval.
The record did not specify in how many countries Beijing Wantai will run the trial. However, it indicated that an ethics committee in the Philippines had approved the study.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine